Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines
Study Details
Study Description
Brief Summary
Vaccination is the best way to mitigate the coronavirus disease 2019 (COVID-19) pandemic, but the vaccine immunogenicity may be quite variable from person to person. There is increasing evidence suggesting that the gut microbiome is a major determinant of vaccine immunogenicity. Thus, the investigators investigated the relationship between gut microbiota and humoral immune response after COVID-19 vaccination.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
ChAdOx1 vaccinated group From Febrary 25, 2021 to July 16, 2021, healthy healthcare workers were prospectively recruited at a tertiary hospital in Seoul, Republic of Korea, and they were assigned to get ChAdOx1 (Oxford/AstraZeneca) (n=26) vaccines. Participants were excluded if they had history of medication which would affect gut microbiota in the past 1 month, including antibiotics, laxatives, and motility drugs; previous history of positive SARS-CoV-2 test on nasopharyngeal PCR; or positive serum Spike IgG results. |
Other: This is observational study
We enrolled the healthcare workers assigned to get either BNT162b2 or ChAdOx1 by the Korean government.
|
BNT162b2 vaccinated group From Febrary 25, 2021 to July 16, 2021, 53 healthy healthcare workers were prospectively recruited at a tertiary hospital in Seoul, Republic of Korea, and they were assigned to get BNT162b2 (n=27) vaccines. Participants were excluded if they had history of medication which would affect gut microbiota in the past 1 month, including antibiotics, laxatives, and motility drugs; previous history of positive SARS-CoV-2 test on nasopharyngeal PCR; or positive serum Spike IgG results. |
Other: This is observational study
We enrolled the healthcare workers assigned to get either BNT162b2 or ChAdOx1 by the Korean government.
|
Outcome Measures
Primary Outcome Measures
- Taxonomic biomarkers predicting immune responses [before the administration of first-dose]
This study aimed to analyze whether fecal microbiota composition before vaccination was associated with immmune response level
Secondary Outcome Measures
- Antibody titres after the first dose vaccination [3weeks from the first-dose administration in BNT162b2 group, 8-12weeks from the first-dose administration in ChAdOx1]
This study aimed to analyze maximum immune response after first dose vaccination
- Antibody titres after the second dose vaccination [3 weeks from the second dose administration in both BNT162b2 and ChAdOx1 groups]
This study aimed to analyze maximum immune response after second dose vaccination
Eligibility Criteria
Criteria
Inclusion Criteria:
-
People assigned to get either BNT162b2 or ChAdOx1 vaccines
-
informed concents
Exclusion Criteria:
- Participants were excluded if they had a history of medication which would affect gut microbiota in the past 1 month, including antibiotics, laxatives, and motility drugs.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Koera University Guro Hospital | Seoul | Korea, Republic of | 08308 |
Sponsors and Collaborators
- Korea University Guro Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2021GR0097